US$280 million in financing further supports human clinical trials of Musk's brain-computer interface company Neuralink

Neuralink, a brain-computer interface startup founded by Musk, recently completed a new round of financing, totaling US$280 million (approximately RMB 2.013 billion). The financing, led by Peter Thiel's Founders Fund, comes months after the company received approval from U.S. regulators to begin its first human clinical trial

Neuralink is a company dedicated to developing chips and devices that can be connected to the human brain. Its goal is to enable humans to control electronic devices through thoughts and treat nervous system-related Disease. The company did not disclose the valuation of this round of financing. The company was valued at about $5 billion in private stock transactions, Reuters reported in June.

On the social media platform X (formerly known as Twitter), Neuralink published an article expressing great excitement for its future development. Last year, employees at the company said that pressure from Musk to obtain approval from the U.S. Food and Drug Administration (FDA) as soon as possible led to a rush on animal experiments that unfortunately resulted in some unnecessary animal deaths. The data generated by these animal experiments will be used to support the company's application for human clinical trials

All articles on this site contain advertising statements, including external jump links (such as hyperlinks, QR codes, passwords, etc.) ), aiming to convey more information and save selection time, the results are for reference only

The above is the detailed content of US$280 million in financing further supports human clinical trials of Musk's brain-computer interface company Neuralink. For more information, please follow other related articles on the PHP Chinese website!